3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Glioblastoma
4
Glioma
3
Multiple Myeloma
2
Lymphoma
2
Astrocytoma
2
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Carcinoma
1
Advanced Fallopian Tube Carcinoma
1
Interventions
Cyclophosphamide
165
fludarabine phosphate
110
Peripheral Blood Stem Cell Transplantation
94
Mycophenolic Acid
88
Whole-Body Irradiation
81
Etoposide
81
Tacrolimus
73
Busulfan
68
Melphalan
67
Filgrastim
66
fludarabine
62
Radiotherapy
56
Doxorubicin
54
Cyclosporine
54
Rituximab
50
Brentuximab Vedotin
48
Antilymphocyte Serum
47
Granulocyte Colony-Stimulating Factor
42
Vinblastine
41
Methotrexate
38
Dacarbazine
37
Cytarabine
35
Gemcitabine
34
Nivolumab
30
Bleomycin
29
Carmustine
28
Vincristine
25
Prednisone
25
Sirolimus
24
Bendamustine Hydrochloride
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hodgkin Disease
×
Tetanus Toxoid
×
Clear all
NCT01611298
2020-04-21
TAR
Baylor College of Medicine
Phase NA
Completed
7 enrolled
8 charts